Search tips
Search criteria

Results 1-6 (6)

Clipboard (0)
more »
Year of Publication
1.  Determinant of Long-Term Quality of Life: Surgery in Breast Cancer Treatment 
Breast Care  2012;7(5):361-362.
PMCID: PMC3518939  PMID: 24647773
2.  Role of Breast Surgery in BRCA Mutation Carriers 
Breast Care  2012;7(5):378-382.
BRCA mutation carriers have a life-long breast cancer risk between 55 and 85% and a high risk of developing breast cancer at a very young age, depending on the type of mutation. The risk of developing contralateral breast cancer after a first breast cancer is elevated up to 65%, especially in case of BRCA1 mutation and young age at the first breast cancer. Since bilateral prophylactic mastectomy is associated with a risk reduction of 90–95% of developing primary or contralateral breast cancer, this option is a key point within the counseling process for patient information and shared decision-making of mutation carriers. Although the local control after breast-conserving therapy in mutation carriers seems to be comparable to that of sporadic breast cancer patients, individual patient information and counseling should include all alternative procedures of oncologically adequate mastectomy techniques and immediate reconstruction. Excellent cosmetic results, high levels of life quality, and good patient acceptance can be achieved with the recent developments in reconstructive surgery of the breast.
PMCID: PMC3518951  PMID: 24647776
BRCA mutation carrier; Mastectomy techniques; Reconstructive surgery of the breast; Prophylactic mastectomy
3.  Sentinel Lymph Node Biopsy in Early Breast Cancer 
Breast Care  2011;6(3):185-191.
The role of axillary surgery for the treatment of primary breast cancer is in a process of constant change. During the last decade, axillary dissection with removal of at least 10 lymph nodes (ALD) was replaced by sentinel lymph node biopsy (SLNB) as a staging procedure. Since then, the indication for SLNB rapidly expanded. Today's surgical strategies aim to minimize the rate of patients with a negative axillary status who undergo ALD. For some subgroups of patients, the indication for SLNB (e.g. multicentric disease, large tumors) or its implication for treatment planning (micrometastatic involvement, neoadjuvant chemotherapy) is being discussed. Although the indication for ALD is almost entirely restricted to patients with positive axillary lymph nodes today, the therapeutic effect of completion ALD is more and more questioned. On the other hand, the diagnostic value of ALD in node-positive patients is discussed. This article reflects today's standards in axillary surgery and discusses open issues on the diagnostic and therapeutic role of SLNB and ALD in the treatment of early breast cancer.
PMCID: PMC3132965  PMID: 21779223
Breast cancer; Surgery; Axillary lymph node dissection; Sentinel lymph node biopsy
4.  Ductal Carcinoma in Situ: Clinical Perspective 
Breast Care  2010;5(4):227-232.
Ductal carcinoma is situ (DCIS) is the fastest growing subtype of breast cancer, mainly because of improved screening activities. In contrast to invasive disease, DCIS is a local process with excellent survival rates. Current treatment strategies include surgery, radiotherapy (RT) and anti-hormonal treatment. The selection of an individual risk-adapted therapeutic approach remains controversial. This relates especially to the extent of surgery and the therapeutic index of adjuvant RT and tamoxifen. Several new trials have been published or updated recently that address important clinical issues. There is an urgent need to get more insight into the biological behaviour of different subtypes of DCIS, and develop more targeted and individualized treatment strategies. So far, surgery appears to be the most effective treatment modality. A morphology-based treatment model that allows complete resection of certain DCIS lesions without further adjuvant measures has not been evaluated prospectively and deserves further evaluation.
PMCID: PMC3346167  PMID: 22590442
Breast cancer; Ductal carcinoma in situ; Surgery; Radiotherapy; Tamoxifen
5.  News from the San Antonio Breast Cancer Symposium 2009 
Breast Care  2010;5(1):38-43.
PMCID: PMC3357166  PMID: 22649330

Results 1-6 (6)